VIA
DYN icon

Virtus Investment Advisers’s Dyne Therapeutics DYN Stock Holding History

Virtus Investment Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Buy
17,988
+3,838
+27% +$71.4K 0.09% 279
2026
Q1 		$257K Buy
14,150
+344
+2% +$5.93K 0.07% 309
2025
Q4 		$270K Buy
13,806
+5,937
+75% +$112K 0.07% 292
2025
Q3 		$99.5K Buy
7,869
+1,366
+21% +$15.6K 0.03% 426
2025
Q2 		$61.9K Buy
6,503
+90
+1% +$991 0.02% 437
2025
Q1 		$67.1K Buy
+6,413
New +$91.7K 0.02% 459

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Virtus Investment Advisers's DYN Position: Q2 2026 in Review

Virtus Investment Advisers increased its Dyne Therapeutics (DYN) stake by 27% in Q2 2026, buying an estimated $71.4K and bringing the position to 17,988 shares worth $400K. The position accounts for 0.09% of the portfolio, ranked #279.

Virtus Investment Advisers first reported a position in DYN in Q1 2025 and has held it in 6 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Virtus Investment Advisers held 17,988 shares of Dyne Therapeutics worth $400K as of Q2 2026.
  • Virtus Investment Advisers bought 3,838 Dyne Therapeutics shares in Q2 2026, an estimated $71.4K.
  • Dyne Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #279 holding.
  • Virtus Investment Advisers first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.